Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2022

01-01-2022 | Lansoprazole | Original Article

Comparative Efficacy of Various Pharmacological Interventions in the Treatment of Functional Dyspepsia: A Network Meta-Analysis

Authors: Liang Liang, Jia Yu, Ling Xiao, Gaohua Wang

Published in: Digestive Diseases and Sciences | Issue 1/2022

Login to get access

Abstract

Background and Aim

Patients with functional dyspepsia often select different pharmacological treatments. We aimed to compare and rank the efficacy of different pharmacological interventions in treating functional dyspepsia.

Methods

We searched EMBASE, PubMed, Cochrane, Web of Science and MEDLINE from the date of database inception to March 28, 2019. A random-effects model was selected to conduct traditional meta-analysis to directly examine the efficacy of different pharmacological interventions. The consistency model was selected to conduct a network meta-analysis to evaluate the relative effects and rank probability of different pharmacological interventions.

Results

We included 58 trials (15,629 participants and 21 pharmacological treatments). Network meta-analysis showed that cisapride, domperidone, itopride, and levosulpiride were better than placebo, especially in short term (< 4 weeks). And levosulpiride was significantly more effective than 15 other drugs and placebo (ORs ranging between 0.05 and 0.15). Cisapride was significantly more effective than lansoprazole (OR 0.30, 95% CrI 0.09–0.99) and tegaserod (OR 0.26, 95% CrI 0.07–0.98). The rank probability showed that levosulpiride was most likely to be rank 1 (77%), cinitapride rank 2 (17%), and cisapride rank 3 (23%).

Conclusions

Our study confirmed the effectiveness of several pharmacological treatments for ameliorating functional dyspepsia. Furthermore, levosulpiride relatively ranked the best in managing FD. Physicians should be encouraged to apply promising pharmacological interventions (e.g., levosulpiride and cisapride). However, the results should be interpreted with caution due to small study effects.
Literature
1.
Guevara L. Gastroduodenal functional disorders. Revista de investigacion clinica organo del Hospital de Enfermedades de la Nutricion 1971;23:221–235PubMed
2.
3.
Aoki S, Haruma K, Kusunoki H, Hata J, Hara M, Yoshida S et al. Evaluation of gastric emptying measured with the 13C-octanoic acid breath test in patients with functional dyspepsia: comparison with ultrasonography. Scand J Gastroenterol 2002;37:662–666PubMedCrossRef
4.
Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Internal Med 1988;108:865–879CrossRef
5.
6.
Bennett EJ, Piesse C, Palmer K, Badcock CA, Tennant CC, Kellow JE. Functional gastrointestinal disorders: psychological, social, and somatic features. Gut 1998;42:414–420PubMedPubMedCentralCrossRef
7.
Jin M, Mo Y, Ye K, Chen M, Liu Y, He C. Efficacy of serotonin receptor agonists in the treatment of functional dyspepsia: a meta-analysis. AMS 2019;15:23–32PubMed
8.
Pittayanon R, Yuan Y, Bollegala NP, Khanna R, Lacy BE, Andrews CN et al. Prokinetics for functional dyspepsia: a systematic review and meta-analysis of randomized control trials. Am J Gastroenterol 2019;114:233–243PubMedCrossRef
9.
Lu Y, Chen M, Huang Z, Tang C. Antidepressants in the treatment of functional dyspepsia: a systematic review and meta-analysis. PloS One 2016;11:e0157798PubMedPubMedCentralCrossRef
10.
Du LJ, Chen BR, Kim JJ, Kim S, Shen JH, Dai N. Helicobacter pylori eradication therapy for functional dyspepsia: systematic review and meta-analysis. World J Gastroenterol 2016;22:3486–3495PubMedPubMedCentralCrossRef
11.
Ford AC, Luthra P, Tack J, Boeckxstaens GE, Moayyedi P, Talley NJ. Efficacy of psychotropic drugs in functional dyspepsia: systematic review and meta-analysis. Gut 2017;66:411–420PubMedCrossRef
12.
Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG et al. Effects of proton-pump inhibitors on functional dyspepsia: a meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007;5:178–185PubMedCrossRef
13.
Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279–301PubMedCrossRef
14.
15.
Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10:ED000142
16.
Yang YJ, Bang CS, Baik GH, Park TY, Shin SP, Suk KT et al. Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis. BMC Gastroenterol 2017;17:83PubMedPubMedCentralCrossRef
17.
Miwa H, Kusano M, Arisawa T, Oshima T, Kato M, Joh T et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol 2015;50:125–139PubMedCrossRef
18.
Hsu YC, Liou JM, Yang TH, Hsu WL, Lin HJ, Wu HT et al. Proton pump inhibitor versus prokinetic therapy in patients with functional dyspepsia: is therapeutic response predicted by Rome III subgroups? J Gastroenterol 2011;46:183–190PubMedCrossRef
19.
Jackson JL, O’Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65–72PubMedCrossRef
20.
Mansi C, Borro P, Giacomini M, Biagini R, Mele MR, Pandolfo N et al. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000;14:561–569PubMedCrossRef
21.
Song CW, Chun HJ, Kim CD, Ryu HS, Choe JG, Hyun JH. Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying. Korean J Intern Med 1998;13:15–21PubMedPubMedCentralCrossRef
22.
al-Quorain A, Larbi EB, al-Shedoki F. A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. Scand J Gastroenterol 1995;30:531–534PubMedCrossRef
23.
Champion MC, MacCannell KL, Thomson AB, Tanton R, Eberhard S, Sullivan SN et al. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. Can J Gastroenterol 1997;11:127–134PubMedCrossRef
24.
Wood SF, Penney SC, Cochran KM. Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients. Scand J Gastroenterol Suppl 1993;195:5–10PubMedCrossRef
25.
de Groot GH, de Both PS. Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. Aliment Pharmacol Ther 1997;11:193–199PubMedCrossRef
26.
De Nutte N, Van Ganse W, Witterhulghe M, Defrance P. Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. Clin Ther 1989;11:62–68PubMed
27.
Franciois IDNN. Nonulcer dyspepsia: efect of the gastrointestinal prokinetic drug cisapride. Curr Ter Res 1987;41:8
28.
Hansen JM, Bytzer P, Schaffalitzky de Muckadell OB. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol 1998;93:368–374PubMedCrossRef
29.
Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002;16:1641–1648PubMedCrossRef
30.
Kellow JE, Cowan H, Shuter B, Riley JW, Lunzer MR, Eckstein RP et al. Efficacy of cisapride therapy in functional dyspepsia. Aliment Pharmacol Ther 1995;9:153–160PubMedCrossRef
31.
Rosch W. Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. Scand J Gastroenterol 1987;22:161–164PubMedCrossRef
32.
Wang B, Liang X, Jia B. A controlled multi-centre clinical trial on cisapride in treatment of functional dyspepsia. Zhonghua Nei Ke Za Zhi 1995;34:180–184PubMed
33.
Yeoh KG, Kang JY, Tay HH, Gwee KA, Tan CC, Wee A et al. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. J Gastroenterol Hepatol 1997;12:13–18PubMedCrossRef
34.
Jm C. Cisapride in chronic dyspepsia: results of a doubleblind, placebo-controlled trial [published erratum appears in Scand]. J Gastroenterol Suppl 1993;195:4
35.
Van Outryve M, De Nutte N, Van Eeghem P, Gooris JP. Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. Scand J Gastroenterol Suppl 1993;195:47–52PubMedCrossRef
36.
Fumagalli I, Hammer B. Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial. Scand J Gastroenterol 1994;29:33–37PubMedCrossRef
37.
Halter F, Miazza B, Brignoli R. Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized. Swiss multicentre study. Scand J Gastroenterol 1994;29:618–623PubMedCrossRef
38.
Carvalhinhos A, Fidalgo P, Freire A, Matos L. Cisapride compared with ranitidine in the treatment of functional dyspepsia. Eur J Gastroenterol Hepatol 1995;7:411–417PubMed
39.
Holtmann G, Gschossmann J, Karaus M, Fischer T, Becker B, Mayr P et al. Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. Aliment Pharmacol Ther 1999;13:1459–1465PubMedCrossRef
40.
Mearin F, Rodrigo L, Perez-Mota A, Balboa A, Jimenez I, Sebastian JJ et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004;2:301–308PubMedCrossRef
41.
Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 2012;61:821–828PubMedCrossRef
42.
Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia—100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil 2010;22:618-e173PubMedCrossRef
43.
Talley NJ, Tack J, Ptak T, Gupta R, Giguere M. Itopride in functional dyspepsia: results of two phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 2008;57:740–746PubMedCrossRef
44.
Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006;354:832–840PubMedCrossRef
45.
Sun JZC, Chu Y, Yuan YZ, Li ZS, Liu XG et al. A multi-center, doubleblind, randomized and controlled trial of itopride hydrochloride in treatment of functional dyspepsia. Shanghai Yixue 2003;26:9
46.
Hong LY, Li GP, Hua HX, Jie C, Hi LNZ, An TD, et al. Itopride in treatment of 104 patients with functional dyspepsia: a randomized, double-blind controlled clinical trial. Chin J New Drugs Clin Remedies 2005.
47.
Mo JZLD, Jiang JH et al. A multi-center clinical trial of itopride hydrochloride in the treatment of functional dyspepsia. Zhongguo Xinyao Zazhi 2003;12:9
48.
Li-Ya Z. A multicentre clinical trial on itopride hydrochloride for treatment of functional dyspepsia. Chin J Clin Pharmacol. 2000.
49.
Zhu CQMY, Zeng MD et al. A clinical study of hydrochloride itopride in the treatment of functional dyspepsia. Zhongguo Yaoke Daxue Xuebao 2005;6:3
50.
Amarapurkar D, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004;102:735–737PubMed
51.
Hallerback BI, Bommelaer G, Bredberg E, Campbell M, Hellblom M, Lauritsen K et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002;16:959–967PubMedCrossRef
52.
Otaka M, Jin M, Odashima M, Matsuhashi T, Wada I, Horikawa Y et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005;21:42–46PubMedCrossRef
53.
Chen SY, Wang JY, Zhu CW, Yuan YZ, Zou B, Xia L et al. A randomized controlled Multi-center clinical trial on mosapride in the treatment of functional dyspepsia. Zhonghua Liu Xing Bing Xue Za Zhi 2004;25:165–168PubMed
54.
Jinkun L, Ming R, Xiaozhong P, Yinglian X, Siyun W, Li Y, et al. Short-term efficacy of mosapride dispersible tablet on postprandial distress syndrome. Chin J Gastroenterol. 2009.
55.
Kinoshita YHT, Kawamura A, Yuki M, Amano K, Sato H et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharm Ther 2005;21:4
56.
Shnhc T. Usefulness of famotidine in functional dyspepsia patient treatment: comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharm Ther 2005;21:6
57.
Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, Chey WD et al. Tegaserod treatment for dysmotility-like functional dyspepsia: results of two randomized, controlled trials. Am J Gastroenterol 2008;103:1906–1919PubMed
58.
Bekhti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J 1979;55:30–32PubMed
59.
Van Outryve M, Lauwers W, Verbeke S. Domperidone for the symptomatic treatment of chronic post-prandial nausea and vomiting. Postgrad Med J 1979;55:33–35PubMed
60.
Van de Mierop L, Rutgeerts L, Van den Langenbergh B, Staessen A. Oral domperidone in chronic postprandial dyspepsia. A double-blind placebo-controlled evaluation. Digestion 1979;19:244–250PubMedCrossRef
61.
Davis RH, Clench MH, Mathias JR. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double-blind, placebo-controlled study. Dig Dis Sci 1988;33:1505–1511PubMedCrossRef
62.
Miwa H, Osada T, Nagahara A, Ohkusa T, Hojo M, Tomita T et al. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol 2006;21:1826–1831PubMedCrossRef
63.
Talley NJ, Riff DS, Schwartz H, Marcuard SP. Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection. Aliment Pharmacol Ther 2001;15:1603–1611PubMedCrossRef
64.
Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW et al. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter. Randomized Controlled Study. Gastroenterology 2015;149:340-349 e342PubMedCrossRef
65.
Kaosombatwattana U, Pongprasobchai S, Limsrivilai J, Maneerattanaporn M, Leelakusolvong S, Tanwandee T. Efficacy and safety of nortriptyline in functional dyspepsia in Asians: a randomized double-blind placebo-controlled trial. J Gastroenterol Hepatol 2018;33:411–417PubMedCrossRef
66.
Tan VP, Cheung TK, Wong WM, Pang R, Wong BC. Treatment of functional dyspepsia with sertraline: a double-blind randomized placebo-controlled pilot study. World J Gastroenterol 2012;18:6127–6133PubMedPubMedCentralCrossRef
67.
van Kerkhoven LA, Laheij RJ, Aparicio N, De Boer WA, Van den Hazel S, Tan AC et al. Effect of the antidepressant venlafaxine in functional dyspepsia: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2008;6:746–752PubMedCrossRef
68.
Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: results depend on Helicobacter pylori status, The Frosch Study Group. Gut 2000;47:473–480PubMedPubMedCentralCrossRef
69.
Bolling-Sternevald E, Lauritsen K, Aalykke C, Havelund T, Knudsen T, Unge P et al. Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand J Gastroenterol 2002;37:1395–1402PubMedCrossRef
70.
Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Raisanen P, Pap A et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998;12:1055–1065PubMedCrossRef
71.
Peura DA, Kovacs TO, Metz DC, Siepman N, Pilmer BL, Talley NJ. Lansoprazole in the treatment of functional dyspepsia: two double-blind, randomized, placebo-controlled trials. Am J Med 2004;116:740–748PubMedCrossRef
72.
Wong WM, Wong BC, Hung WK, Yee YK, Yip AW, Szeto ML et al. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002;51:502–506PubMedPubMedCentralCrossRef
73.
van Zanten S, Armstrong D, Chiba N, Flook N, White R, Chakraborty B et al. Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled “ENTER” trial. Am J Gastroenterol 2006;101:2096–2106PubMedCrossRef
74.
Du Y, Su T, Song X, Gao J, Zou D, Zuo C et al. Efficacy and safety of cinitapride in the treatment of mild to moderate postprandial distress syndrome-predominant functional dyspepsia. J Clin Gastroenterol 2014;48:328–335PubMedCrossRef
75.
Song C, Chun H, Kim C, Ryu H, Choe J, Hyun J. Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying. Korean J Internal Med 1998;13:15–21CrossRef
Metadata
Title
Comparative Efficacy of Various Pharmacological Interventions in the Treatment of Functional Dyspepsia: A Network Meta-Analysis
Authors
Liang Liang
Jia Yu
Ling Xiao
Gaohua Wang
Publication date
01-01-2022
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2022
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-06846-1

Other articles of this Issue 1/2022

Digestive Diseases and Sciences 1/2022 Go to the issue

EDITORIAL

Does Fellow Participation Increase the Adenoma Detection Rate?

Mentored Review

Is the Medium Still the Message? Culture-Independent Diagnosis of Gastrointestinal Infections

Review

Nonalcoholic Fatty Pancreas Disease: Role in Metabolic Syndrome, “Prediabetes,” Diabetes and Atherosclerosis

Review

Update: Innate Lymphoid Cells in Inflammatory Bowel Disease

DDS–SIRC COOPERATIVE CONFERENCES

AL Lambda Amyloidosis Activates Acute Liver Failure in the Absence of Plasma Cell Dyscrasia

Original Article

CaMKII Mediates TGFβ1-Induced Fibroblasts Activation and Its Cross Talk with Colon Cancer Cells
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits